Oral RSV Vaccine - Preclinical Data Published in Vaccine
June 27 2018 - 8:00AM
Business Wire
Vaxart, Inc. (Nasdaq:VXRT), a clinical-stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced publication of
the preclinical results of its oral F-protein based Respiratory
Syncytial Virus (RSV-F) vaccine. The findings were published in the
most recent online version of Vaccine (Joyce C. et al.,
“Orally administered adenoviral-based vaccine induces respiratory
mucosal memory and protection against RSV infection in cotton
rats”).
As described in the article, the oral RSV-F vaccine candidate
provided complete sterilizing protection against RSV infection in
the cotton rat challenge model at the target dose. The vaccine
induced significant and dose-dependent neutralizing antibody
responses in serum, as well as multi-functional effector and memory
B cell responses at the mucosal surface along the respiratory
tract. Importantly, the Vaxart oral RSV-F vaccine did not cause any
inflammatory pathology in the respiratory tract.
“Based on these results, we believe that our proprietary
platform is uniquely suited as the optimal delivery system for an
RSV vaccine,” said Sean Tucker, Ph.D., founder and chief scientific
officer of Vaxart. “We were particularly pleased with the strong
mucosal immune responses that were generated in the respiratory
tract. Those trended higher even than those observed after natural
infection with RSV, establishing a first line of defense against
RSV infection in the respiratory tract itself. These data add to
the increasing body of evidence that suggests our vaccines may
provide protection through both systemic and mucosal immunity, a
phenomenon we have also observed in our H1 influenza human
challenge study. RSV is an important public health issue, and we
look forward to building on these results.”
About Respiratory Syncytial Virus (RSV)
RSV is a major cause of acute upper (colds) and lower (pneumonia
and bronchiolitis) respiratory tract infections in infants, young
children, and adults. Each year in the United States, RSV
accounts for an estimated 2.1 million medical visits in children
under the age of five, with many of the children afflicted
requiring hospitalization. The CDC estimates that each year in the
United States, more than 177,000 older adults are hospitalized and
14,000 of them die due to RSV infection. At the present time there
is no effective vaccine to prevent or recommended therapy to treat
RSV infections.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tablet vaccines are
easier to distribute and administer than injectable vaccines, and
have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV). For more information, please visit
www.vaxart.com.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential”,
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates and clinical results and trial data,. Vaxart may
not actually achieve the plans, carry out the intentions or meet
the expectations or projections disclosed in our forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Actual results or events could differ
materially from the plans, intentions, expectations and projections
disclosed in the forward-looking statements. Various important
factors could cause actual results or events to differ materially
from the forward-looking statements that Vaxart makes, that
Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; and the risks described in the
“Risk Factors” sections of Vaxart’s Quarterly Report filed on Form
10-Q for the quarter ended March 31, 2018 and of Vaxart’s other
periodic reports filed with the SEC. Vaxart does not assume any
obligation to update any forward-looking statements, except as
required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180627005388/en/
Stern Investor RelationsCarl Mauch,
212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Apr 2023 to Apr 2024